Noopur Raje

Noopur Raje is a translational researcher who uniquely bridges T-cell immunotherapy and myeloma bone biology. As Director of the Center for Multiple Myeloma at Massachusetts General Hospital and Rita M. Kelley Chair in Oncology, she has built one of America's leading academic myeloma programs since 2005. Her participation in MagnetisMM trials contributed to FDA approval of elranatamab (2023), while her laboratory research on RANK/RANKL signaling led to denosumab approval for myeloma bone disease. She serves as Secretary of the International Myeloma Society. With 744 publications and 51,763 citations (D-index 107), Raje ranks among the world's most influential myeloma researchers.

Noopur Raje博士是一位独特地连接T细胞免疫治疗和骨髓瘤骨生物学的转化研究者。作为麻省总医院多发性骨髓瘤中心主任和Rita M. Kelley肿瘤学讲席教授，自2005年以来她建立了美国领先的学术骨髓瘤项目之一。她参与MagnetisMM试验促成了elranatamab的FDA批准（2023年），同时她关于RANK/RANKL信号通路的实验室研究促成了denosumab用于骨髓瘤骨病的批准。她担任国际骨髓瘤学会秘书长。凭借744篇出版物和51,763次引用（D指数107），Raje位列全球最具影响力的骨髓瘤研究者之列。